5 Marathons in 5 Days for Charlie
Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy
Capsida Receives FDA IND Clearance for Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy
Capsida to Present Progress Updates on CAP-002 at the ASGCT Annual Meeting
STXBP1 Census - Q1 2025
Small Town. Loud Voice.
What happens when a rare disease drug seems to work, but the health care system doesn’t?
Orphan Disease Center 2024 Million Dollar Bike Ride Grants - $139,416 for STXBP1 Research Awarded
STXBP1 Foundation Accelerates Growth with Addition of New Executive Director